ESR1 and breast cancer: In the single-arm GIADA-trial, a pCR rate of 15% was observed after neo-adjuvant chemotherapy (AC) plus nivolumab and exemestane in high-risk ER+ ( ≥ 10%) breast cancer, defined by high Ki-67 expression and/or tumor grade 38.